Clinical and histologic signs of regression two months after initiation of treatment with dabrafenib and trametinib in a case of stage IIIc BRAF V600E-positive scalp melanoma

被引：0
|
作者：
Wei, Erin [1 ]
Cordero, Roberto Ruiz [2 ]
Zhou, Xiaolong [1 ]
Feun, Lynn [3 ]
Thomas, Giovanna [4 ]
Cho-Vega, Jeong Hee [2 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Pathol, Dermatopathol, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Med Hematol Oncol, Miami, FL 33136 USA
[4] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2015年 / 72卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
269
引用
收藏
页码：AB165 / AB165
页数：1
相关论文
共 41 条
  • [1] Treatment of a patient with conjunctival melanoma and V600E-positive BRAF mutation status with Vemurafenib
    Kiecker, Felix
    Ewald, Kerstin
    Bertelmann, Eckart
    Trefzer, Uwe
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2012, 10 (09): : 690 - 690
  • [2] TREATMENT OF THREE DIFFERENT BRAF-V600E POSITIVE BRAIN TUMORS WITH VEMURAFENIB AND DABRAFENIB/TRAMETINIB: A CASE SERIES
    Dhir, Nikita
    Chandrahas, Sheila
    O'Suoji, Chibuzo
    Al-Rahawan, Mohamad
    NEURO-ONCOLOGY, 2020, 22 : 90 - 90
  • [3] Potential immune-related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma
    Morgese, Francesca
    Cognigni, Valeria
    Scortichini, Laura
    Ranallo, Nicoletta
    Lunerti, Valentina
    Migliore, Antonella
    Tronconi, Francesca
    Berardi, Rossana
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 18 (01)
  • [4] Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report
    Taniguchi, Yoshihiko
    Tamiya, Akihiro
    Yanagisawa, Atsushi
    Shimaya, Minako
    Kawakami, Mayu
    Inagaki, Yuji
    Saijo, Nobuhiko
    Matsuda, Yoshinobu
    Okishio, Kyoichi
    THORACIC CANCER, 2023, 14 (13) : 1201 - 1203
  • [5] Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
    Jafri, Sabih
    Yaqub, Abid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [6] Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a US Commercial Payer Perspective
    Stellato, Daniel
    Gerbasi, Margaret E.
    Ndife, Briana
    Ghate, Sameer R.
    Moynahan, Aaron
    Mishra, Dinesh
    Gunda, Praveen
    Koruth, Roy
    Delea, Thomas E.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1227 - +
  • [7] Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
    Gerbasi, Margaret E.
    Stellato, Daniel
    Ghate, Sameer R.
    Ndife, Briana
    Moynahan, Aaron
    Mishra, Dinesh
    Gunda, Praveen
    Koruth, Roy
    Delea, Thomas E.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) : 1243 - 1252
  • [8] A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
    Tronconi, Maria Chiara
    Marinello, Arianna
    Solferino, Alessandra
    Grimaudo, Susanna
    Ciccarelli, Michele
    Manara, Sofia
    Cozzaglio, Luca
    Mancini, Luca
    Borroni, Riccardo
    Santoro, Armando
    CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 560 - 565
  • [9] COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
    Hauschild, A.
    Santinami, M.
    Long, G. V.
    Atkinson, V.
    Mandala, M.
    Sileni, V. Chiarion
    Nyakas, M. S.
    Dutriaux, C.
    Haydon, A.
    Robert, C.
    Mortier, L.
    Schachter, J.
    Ji, R.
    Zhang, P.
    Mookerjee, B.
    Legos, J.
    Kefford, R.
    Dummer, R.
    Kirkwood, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
    Wang, T. W.
    Smith, J. L.
    Carlino, M.
    Burmeister, B.
    Pinkham, M. B.
    Fogarty, G. B.
    Christie, D.
    Estall, V.
    Shackleton, M.
    Wolfe, R.
    Phuong, T. L. T.
    Paton, E. J.
    Steel, V.
    Williams, N. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
12345